ASH 2022: Recent Advances in Chronic Myeloid Leukemia


Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Data from the following clinical trials are discussed:

  • 620: Three-Year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
  • 333: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
  • 3009: Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
  • 4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Related Videos
Debu Tripathy, MD
Lori A. Leslie, MD
Debu Tripathy, MD
Changchun Deng, MD, PhD
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD